Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume.

Area of Science:

• Urology
• Oncology
• Medical Imaging

Background:

• Prostate specific antigen density (PSAd) is a key predictor of clinically-significant prostate cancer (csPCa).
• Limited data exists on how prostate volume impacts PSAd's diagnostic performance.
• This study aimed to evaluate PSAd accuracy for csPCa across different prostate volumes.

Purpose of the Study:

• To determine the diagnostic accuracy of PSAd in predicting csPCa.
• To analyze how prostate volume influences the sensitivity and specificity of PSAd.
• To assess the utility of PSAd thresholds across varying prostate sizes.

Main Methods:

• Retrospective analysis of 548 patients undergoing MRI and biopsy.
• Patients categorized into small (≤30 mL), medium (>30 to <50 mL), and large (≥50 mL) prostate volume groups.
• PSAd sensitivity and specificity evaluated at thresholds of ≥0.10, ≥0.15, and ≥0.20 ng/mL/mL for csPCa.

Main Results:

• PSAd diagnostic performance significantly differed across prostate volume groups.
• Sensitivity for csPCa was highest in small prostates and lowest in large prostates.
• Specificity showed an inverse trend, being lowest in small and highest in large prostates.

Conclusions:

• A single PSAd threshold is insufficient for accurate csPCa prediction across all prostate volumes.
• Using uniform PSAd thresholds may lead to missed csPCa diagnoses in men with larger prostates.
• Tailoring PSAd thresholds to prostate volume categories can enhance csPCa risk assessment and guide biopsy decisions.